Literature DB >> 11007110

Palliative decompression of obstructive hilar malignancies utilizing an extrahilar biliary approach.

S Yilmaz1, V Kirimlioglu, D A Katz, M Caglikulekci, M Yilmaz.   

Abstract

Hilar cancers carry a dismal prognosis. Palliation of obstructive jaundice in patients with hilar cancer can be achieved by either surgical or nonsurgical means. Selection of the appropriate palliative measures is a challenging problem. Segmental bilioenteric anastomosis procedures were performed on 19 patients with hilar cancer. Seventeen of the bypasses were done to the segment III duct, known as the ligamentum teres approach, and two bypasses were to the segment V duct. Five patients, who had already been stented percutaneously or endoscopically, were operated on after the stents were clogged and a duodenal obstruction ensued. There were two postoperative deaths (10.5%) and four postoperative complications (21%). All of the 17 surviving patients experienced improvement in the level of jaundice postoperatively and the levels of serum total and direct bilirubin decreased by 78.9% and 84.2%, respectively. Two patients developed late cholangitis before death and were treated by external biliary drainage; one developed duodenal obstruction and was treated by gastrointestinal anastomosis. The mean length of hospital stay was 15.2 days. Mean survival was 8.2 months and the mean period of well-being was 7.8 months. Median survival was 7 months and median period of well being was 7 months. Three patients are still alive at 8, 8, and 24 months. These data suggest that the ligamentum teres approach offers effective palliation for patients with unresectable hilar cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11007110     DOI: 10.1023/a:1005569128877

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  38 in total

1.  Pitfalls of percutaneous-endoscopic biliary stent placement.

Authors:  P C Tam; E C Lai; W M Hui; S C Chan
Journal:  Am J Gastroenterol       Date:  1990-02       Impact factor: 10.864

2.  Left intrahepatic cholangio-enteric anastomosis (round ligament approach): an effective palliative treatment for hilar cancers.

Authors:  O Traynor; D Castaing; H Bismuth
Journal:  Br J Surg       Date:  1987-10       Impact factor: 6.939

3.  Bypass procedure for bile duct cancer.

Authors:  K Miyazaki; K Nagafuchi; F Nakayama
Journal:  World J Surg       Date:  1988-02       Impact factor: 3.352

4.  Skeletization resection and central hepatic resection in the treatment of bile duct cancer.

Authors:  T T White
Journal:  World J Surg       Date:  1988-02       Impact factor: 3.352

5.  Radical resection and liver grafting as the two main components of surgical strategy in the treatment of proximal bile duct cancer.

Authors:  R Pichlmayr; B Ringe; W Lauchart; W O Bechstein; G Gubernatis; E Wagner
Journal:  World J Surg       Date:  1988-02       Impact factor: 3.352

6.  Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice.

Authors:  J R Andersen; S M Sørensen; A Kruse; M Rokkjaer; P Matzen
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

7.  Effective palliation of malignant biliary duct obstruction.

Authors:  M A Malangoni; D M McCoy; J D Richardson; L M Flint
Journal:  Ann Surg       Date:  1985-05       Impact factor: 12.969

8.  Surgical strategy for the management of hilar bile duct cancer.

Authors:  Y Parc; P Frileux; P Balladur; E Delva; L Hannoun; R Parc
Journal:  Br J Surg       Date:  1997-12       Impact factor: 6.939

9.  Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation.

Authors:  S Iwatsuki; S Todo; J W Marsh; J R Madariaga; R G Lee; I Dvorchik; J J Fung; T E Starzl
Journal:  J Am Coll Surg       Date:  1998-10       Impact factor: 6.113

10.  Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver.

Authors:  H Bismuth; M B Corlette
Journal:  Surg Gynecol Obstet       Date:  1975-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.